Reny Retnaningsih, Endang Wahyuni, Kusnarman Keman
Introduction: Immunocontraception of zone pellucide (ZP3) is known causing disturbance of gap junction which inhibits transport growth factor such as bone morphogenetic protein (BMP-15). Decreased BMP-15 generates disturbance of proliferation and differentiation of follicle, granulosa, and techa cells. Anti-Human ZP3 monoclonal antibody with high specificity is being developed to prevent such effects. This study aimed to evaluate the effect of MabhZP3 on the expression of BMP-15 and number of preantral and antral follicles in the ovary of mice. Materials and Methods: This was true experiment post-test only control group design. Subjects involved were 48 mice (Mus musculus) that were divided into control (adjuvant) and treatment group (Mab-hZP3 with dose of 20 µg, 40 µg, and 60 µg). In each group, a fraction of mice were killed at day 10, 15 and 20. Measurement of BMP-15 was performed with immunohistochemical, assessment, and a number of preantral and antral follicles was measured with hematoxylin and eosin. Results: Overall, results showed that there was no significant difference in the effects of Mab-hZP3 in a dose range of 20-60 µg on the expression of BMP-15 and number of preantral and antral follicles. A similar finding was also observed in the period of 10-20 days. Such results are suggested to be associated with the specificity of the monoclonal antibody. Conclusions: Anti-Human ZP3 monoclonal antibody has no effect on decreasing expression of BMP-15 and number of preantral and antral follicles. It is considered as effective and safe immunocontraception. © 2017 Turkish Journal of Immunology. All rights reserved.
Department of Midwifer, Faculty of Medicine, Brawijayac University, Malang, Indonesia; Department of Physiology, Faculty of Medicine, Brawijayac University, Malang, Indonesia; Department of Obstetrics and Gynecology, Saiful Anwar Public Hospital, Malang, Indonesia
